An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity (Q39132688)

From Wikidata

Jump to navigation Jump to search

scientific article published on 7 August 2009

Language	Label	Description	Also known as
English	An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity	scientific article published on 7 August 2009

Statements

scholarly article

1 reference

Europe PubMed Central

9 September 2017

An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity (English)

1 reference

Europe PubMed Central

9 September 2017

0 references

vector-borne disease

0 references

1 reference

based on heuristic

inferred from title

3

object named as

Navin Khanna

1 reference

Europe PubMed Central

9 September 2017

Sathyamangalam Swaminathan

4

object named as

Sathyamangalam Swaminathan

1 reference

Europe PubMed Central

9 September 2017

author name string

Saima Khanam

1

1 reference

Europe PubMed Central

9 September 2017

Rajendra Pilankatta

2

1 reference

Europe PubMed Central

9 September 2017

language of work or name

0 references

publication date

7 August 2009

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

27

1 reference

Europe PubMed Central

9 September 2017

43

1 reference

Europe PubMed Central

9 September 2017

6011-6021

1 reference

Europe PubMed Central

9 September 2017

Dengue: recent advances in biology and current status of translational research

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Dengue fever: new paradigms for a changing epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

The future of dengue vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Vaccines against dengue: a review of current candidate vaccines at advanced development stages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Towards a dengue vaccine: progress to date and remaining challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Construction and Characterization of a Single-Cycle Chimeric Flavivirus Vaccine Candidate That Protects Mice against Lethal Challenge with Dengue Virus Type 2

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induced neutralizing antibodies and resistance to Dengue 4 virus challenge in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Replication-Defective Adenoviral Vaccine Vector for the Induction of Immune Responses to Dengue Virus Type 2

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Two Complex, Adenovirus-Based Vaccines That Together Induce Immune Responses to All Four Dengue Virus Serotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Pediatric Measles Vaccine Expressing a Dengue Antigen Induces Durable Serotype-specific Neutralizing Antibodies to Dengue Virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

A ligand-binding pocket in the dengue virus envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Structure of dengue virus: implications for flavivirus organization, maturation, and fusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Characterization of Dengue Virus Complex-Specific Neutralizing Epitopes on Envelope Protein Domain III of Dengue 2 Virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Localization of a neutralizing epitope on the envelope protein of dengue virus type 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Amino acid and phenotypic changes in dengue 2 virus associated with escape from neutralisation by IgM antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Identification of epitopes on the envelope (E) protein of dengue 2 and dengue 3 viruses using monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Adenovirus-vectored vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

A simplified system for generating recombinant adenoviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Ectopic expression of the coxsackievirus and adenovirus receptor increases susceptibility to adenoviral infection in the human cervical cancer cell line, SiHa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Functional and selective targeting of adenovirus to high-affinity Fcgamma receptor I-positive cells by using a bispecific hybrid adapter

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Neutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.07.073

1 reference

Europe PubMed Central

9 September 2017

release_mhjnca5amfglxaxxl4t3m37shu

1 reference

https://api.fatcat.wiki/v0/release/mhjnca5amfglxaxxl4t3m37shu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

9 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39132688&oldid=1949456755"